CML (Chronic Myelogenous Leukemia)
10
2
2
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.0%
1 terminated out of 10 trials
83.3%
-3.2% vs benchmark
10%
1 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Ropeginterferon for Treatment Free Remission
ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
IIT PH1 KDS-1001 in Patients With CML
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
A Study for PRO of CML in Real Word
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
Vascular Dysfunction and Antiangiogenic Therapy
Stem Cell Transplantation for Patients With Cancers of the Blood
Improving Blood Stem Cell Collection and Transplant Procedures